Yazar "Özdemir, İlknur" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Antimicrobial activities of bis-(N-alkylbenzimidazole)-cobalt(II) and zinc (II) complexes
    (2023) Şahin, Neslihan; Üstün, Elvan; Özdemir, İlknur; Günal, Selami; Özdemir, Namık; Bülbül, Hakan; Gürbüz, Nevin; Özdemir, İsmail; Semeril, David
    Eight benzimidazole precursors (L), namely 1-allyl-benzimidazole, 1-methallyl-benzimidazole, 1-isopropyl-benzimidazole, 1-(3-methyloxetan-3-yl)methyl-benzimidazole, 1-allyl-5,6-dimethyl-benzimidazole, 1-methallyl-5,6- dimethyl-benzimidazole, 1-isopropyl-5,6-dimethyl-benzimidazole and 1-(3-methyloxetan-3-yl)methyl-5,6- dimethyl-benzimidazole, were coordinated to cobalt(II) and zinc(II) cations to form complexes of the type [MCl2L2]. Single-crystal X-ray structures were determined for two cobalt(II) and for one zinc(II) complexes and confirmed their tetrahedral molecular geometry. The antibacterial and antifungal activities of these two series of cobalt(II) and zinc(II) complexes were studied against Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae), Gram-positive (Staphylococcus aureus, methicillin-resistant S. aureus and Enterococcus faecalis) bacteria and fungal strains (Candida albicans and Candida glabrata). Overall, cobalt(II) complexes were more effective than the zinc(II) complexes against all microorganisms. The most significant results were obtained with the two dichloro-bis(1-allyl-5,6-dimethylbenzimidazole)-cobalt(II) and dichloro-bis(1-methallyl-5,6-dimethylbenzimidazole)-cobalt(II) complexes against Candida albicans and Candida glabrata fungi with measured minimal inhibitory concentrations as low as 0.024 μmol/mL, values close to those obtained with the commercially available drug Flucanozole (0.020 μmol/mL).
  • Küçük Resim Yok
    Öğe
    Antimicrobial activities of bis-(N-alkylbenzimidazole)-cobalt(II) and zinc(II) complexes
    (Elsevier B.V., 2023) Şahin, Neslihan; Üstün, Elvan; Özdemir, İlknur; Günal, Selami; Özdemir, Namık; Bülbül, Hakan; Gürbüz, Nevin
    Eight benzimidazole precursors (L), namely 1-allyl-benzimidazole, 1-methallyl-benzimidazole, 1-isopropyl-benzimidazole, 1-(3-methyloxetan-3-yl)methyl-benzimidazole, 1-allyl-5,6-dimethyl-benzimidazole, 1-methallyl-5,6-dimethyl-benzimidazole, 1-isopropyl-5,6-dimethyl-benzimidazole and 1-(3-methyloxetan-3-yl)methyl-5,6-dimethyl-benzimidazole, were coordinated to cobalt(II) and zinc(II) cations to form complexes of the type [MCl2L2]. Single-crystal X-ray structures were determined for two cobalt(II) and for one zinc(II) complexes and confirmed their tetrahedral molecular geometry. The antibacterial and antifungal activities of these two series of cobalt(II) and zinc(II) complexes were studied against Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae), Gram-positive (Staphylococcus aureus, methicillin?resistant S. aureus and Enterococcus faecalis) bacteria and fungal strains (Candida albicans and Candida glabrata). Overall, cobalt(II) complexes were more effective than the zinc(II) complexes against all microorganisms. The most significant results were obtained with the two dichloro-bis(1-allyl-5,6-dimethylbenzimidazole)-cobalt(II) and dichloro-bis(1-methallyl-5,6-dimethylbenzimidazole)-cobalt(II) complexes against Candida albicans and Candida glabrata fungi with measured minimal inhibitory concentrations as low as 0.024 ?mol/mL, values close to those obtained with the commercially available drug Flucanozole (0.020 ?mol/mL). © 2023
  • Küçük Resim
    Öğe
    Design, synthesis, antimicrobial activity and molecular docking study of cationic bis?benzimidazole?silver(I) complexes
    (2023) Üstün, Elvan; Şahin, Neslihan; Özdemir, İlknur; Günal, Selami; Gürbüz, Nevin; Özdemir, İsmail; Semeril, David
    Two series of bis(1‐alkylbenzimidazole)silver(I) nitrate and bis(1‐alkyl‐5,6‐ dimethylbenzimidazole)silver(I) nitrate complexes, in which the alkyl substituent is either an allyl, a 2‐methylallyl, an isopropyl or a 3‐methyloxetan‐3‐yl‐methyl chain, were synthesized and fully characterized. The eight N‐coordinated silver(I) complexes were screened for both antimicrobial activities against Gram‐negative (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii) and Gram‐positive (Staphylococcus aureus, Staphylococcus aureus MRSA, and Enterococcus faecalis) bacteria and antifungal activities against Candida albicans and Candida glabrata strains. Moderate minimal inhibitory concentrations (MIC) of 0.087 μmol/mL were found when the Gram‐negative and Gram‐positive bacteria were treated with the silver complexes. Nevertheless, MIC values of 0.011 μmol/mL, twice lower than for the well‐known fluconazole, against the two fungi were measured. In addition, molecular docking was carried out with the structure of Escherichia coli DNA gyrase and CYP51 from the pathogen Candida glabrata with the eight organometallic complexes, and molecular reactivity descriptors were calculated with the density functional theory‐based calculation methods.
  • Küçük Resim
    Öğe
    Synthesis, antimicrobial activity and molecular docking study of benzyl functionalized benzimidazole silver(I) complexes
    (2023) Arı, Erkan; Şahin, Neslihan; Üstün, Elvan; Dündar, Muhammed; Karcı, Hüseyin; Özdemir, İlknur; Koç, Ahmet; Gürbüz, Nevin; Özdemir, İsmail
    In this study, a series of N-functionalized benzimidazole silver(I) complexes were prepared and characterized by FT-IR, 1H, 13C{1H} NMR spectroscopy, and elemental analysis. Synthesized N-benzylbenzimidazole silver(I) complexes were evaluated for their antimicrobial activities against bacteria Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and the fungal strains Candida albicans and Candida glabrata. The results indicated that N-alkylbenzimidazole silver(I) complexes exhibited good antimicrobial activity compared to N-alkylbenzimidazole derivatives. Especially, complex 2e presented perfect antimicrobial activity than the other complexes. The characterized molecules were optimized by DFT-based calculation methods and the optimized molecules were analyzed in detail by molecular docking methods against bacterial DNA-gyrase and CYP51. The amino acid residues detected for both target molecules are consistent with expectations, and the calculated binding affinities and inhibition constants are promising for further studies.